Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
TP53
acute myeloid leukemia (AML)
decitabine
outcome
venetoclax
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 10 2021
15 10 2021
Historique:
revised:
05
05
2021
received:
20
03
2021
accepted:
17
05
2021
pubmed:
14
7
2021
medline:
11
3
2022
entrez:
13
7
2021
Statut:
ppublish
Résumé
TP53 mutation (TP53 Patients with newly diagnosed AML received decitabine 20 mg/m Among 118 patients (median age, 72 years; age range, 49-89 years), 63 (53%) had secondary AML, 39 (33%) had AML with complex karyotype, and 35 (30%) had TP53 Patients with TP53
Sections du résumé
BACKGROUND
TP53 mutation (TP53
METHODS
Patients with newly diagnosed AML received decitabine 20 mg/m
RESULTS
Among 118 patients (median age, 72 years; age range, 49-89 years), 63 (53%) had secondary AML, 39 (33%) had AML with complex karyotype, and 35 (30%) had TP53
CONCLUSIONS
Patients with TP53
Identifiants
pubmed: 34255353
doi: 10.1002/cncr.33689
pmc: PMC10462434
mid: NIHMS1917432
doi:
Substances chimiques
Bridged Bicyclo Compounds, Heterocyclic
0
Sulfonamides
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Decitabine
776B62CQ27
venetoclax
N54AIC43PW
Banques de données
ClinicalTrials.gov
['NCT03404193']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3772-3781Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA231364
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA235622
Pays : United States
Informations de copyright
© 2021 American Cancer Society.
Références
Cancer Discov. 2019 Jul;9(7):910-925
pubmed: 31048320
Lancet Haematol. 2020 Oct;7(10):e724-e736
pubmed: 32896301
Cancer. 2021 Nov 15;127(22):4213-4220
pubmed: 34343352
Leukemia. 2009 Jan;23(1):203-6
pubmed: 18596741
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Leuk Res. 2015 Mar;39(3):348-54
pubmed: 25573287
Leuk Lymphoma. 2014 Jul;55(7):1533-7
pubmed: 24144313
Nat Med. 2020 Oct;26(10):1549-1556
pubmed: 32747829
Am J Hematol. 2019 Jul;94(7):757-766
pubmed: 30963592
Best Pract Res Clin Haematol. 2019 Jun;32(2):134-144
pubmed: 31203995
Cancer Cell. 2017 Dec 11;32(6):748-760.e6
pubmed: 29232553
Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8
pubmed: 20368434
Lancet Oncol. 2018 Feb;19(2):216-228
pubmed: 29339097
N Engl J Med. 2016 Nov 24;375(21):2023-2036
pubmed: 27959731
Clin Lab Med. 2017 Dec;37(4):787-802
pubmed: 29128069
Lancet Haematol. 2019 Jan;6(1):e29-e37
pubmed: 30545576
Cancer. 2016 Nov 15;122(22):3484-3491
pubmed: 27463065
Leuk Lymphoma. 2018 Sep;59(9):2238-2241
pubmed: 29338567
Cold Spring Harb Perspect Biol. 2010 Jan;2(1):a001008
pubmed: 20182602
Blood Adv. 2020 Nov 24;4(22):5681-5689
pubmed: 33211826
N Engl J Med. ;376(8):796-7
pubmed: 28229579
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Ann Hematol. 2020 Mar;99(3):501-511
pubmed: 31965269
Br J Haematol. 2019 Oct;187(2):e45-e48
pubmed: 31441045
Blood. 2020 Mar 12;135(11):791-803
pubmed: 31932844
N Engl J Med. 2020 Aug 13;383(7):617-629
pubmed: 32786187